La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Dolphin Entertainment a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Dolphin Entertainment..

Dolphin Entertainment (NASDAQ:DLPN) Azioni, Catena delle Opzioni

Dolphin Entertainment

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

Dolphin Entertainment, Inc. - Common Stock

Dolphin Entertainment Inc

- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection against infection -
- Vaccine candidates were safe and well-tolerated across all dose groups with no vaccine-related serious adverse events reported -
- Conference call today at 8:30 a.m. ET -
SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today reported positive topline results from the Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine constructs head-to-head against its first-generation constructs.
The open-label, Phase 1 trial was conducted in 60 healthy volunteers who were randomized to receive the first-generation constructs, an equivalent dose of the second-generation GI.1 and GII.4 constructs, or a lower dose of the second-generation constructs (n=20 for each group). The primary immunological endpoint was norovirus blocking antibody assay (NBAA) titer at Day 0 and Day 28. In a Phase 2 challenge trial of the first-generation vaccine constructs, these functional NBAA titers correlated with protection against norovirus infection. Although the study was not powered to determine superiority by statistical methods, the increase in NBAA titers with the second-generation constructs was sufficiently large (141% for the GI.1 construct and 94% for the GII.4 construct) to demonstrate statistical significance at the higher dose.

News

VXRT

Vaxart Reports Topline Results From Phase 1 Clinical Trial Evaluating Second-Generation Oral Pill Norovirus Vaccine Constructs Head-To-Head Against Its First-Generation Constructs

Financing

SLNH

Soluna Holdings Enters $20M Financing With Spring Lane Capital For A 35 MW Phase Of Project Kati 1 Data Center

Blackline Safety (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BLN#TSX">BLN</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $35.94 million which missed the analyst consensus estimate of $37.64 million by 4.52 percent. This is a 13.81 percent increase over sales of $31.58 million the same period last year.

Earnings

Earnings Misses

TSX:BLN

Blackline Safety Q2 EPS $(0.04) Misses $(0.03) Estimate, Sales $35.94M Miss $37.64M Estimate

Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) on Wednesday announced progress in the design and planning of its upcoming Phase 3 trial evaluating AD04, the company's lead investigational genetically targeted, serotonin-3 receptor antagonist, a<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener"> therapeutic agent for Alcohol Use</a> Disorder (AUD) in heavy drinking patients (defined as &lt; 8 drinks/day).
As part of its Phase 3 trial preparation, Adial engaged Cytel Inc., a provider of data science and advanced statistical methodologies for clinical trials, to provide expert support on trial design and data interrogation.
Cytel's contributions have helped inform key design elements of Adial's upcoming trial, which aims to maximize efficiency, cost-effectiveness, and the likelihood of success.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43938875/exclusive-after-fda-response-adial-starts-manufacturing-clinical-supplies-for-upcoming-phase-3-program-of-lead-candidate-for-alcohol-use-disorder" rel="noreferrer noopener">EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder</a>
In part, Cytel's efforts identified specific genetic subpopulations potentially more responsive to AD04, enabling a refined Phase 3 strategy that aligns with clinical and regulatory expectations.
<h2 class="wp-block-heading">Highlights:</h2>
Post-hoc historical clinical trial data analyses identified genotype-defined patient subgroups likely to benefit most from AD04. This supports Adial's precision medicine approach in the upcoming Phase 3 trial, which targets higher efficacy and commercial differentiation.
Adial partnered with Cytel to apply advanced statistical analytics and simulation modeling to optimize the trial design, enable adaptive enrichment, and align with regulatory expectations.
The Phase 3 trial is expected to begin in late 2025, with the potential for interim analysis-driven readouts supporting a streamlined path to potential regulatory submission.
<h2 class="wp-block-heading">Why It Matters</h2>
Adial said in a statement on Wednesday that AD04 represents a first-in-class opportunity in the multi-billion-dollar global AUD market and that its refined clinical strategy will accelerate value realization.
In May, the U.S. Food and Drug Administration&nbsp;(FDA) granted the company's request for an End of Phase 2 meeting to discuss its proposed clinical development plan and seek the U.S. Food and Drug Administration (FDA) guidance on the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45283047/exclusive-adial-pharmaceuticals-secures-fda-end-of-phase-2-meeting-request-to-discuss-upcoming-clinical-development-plan-for-lead-program" rel="noreferrer noopener">Phase 3 trial for AD04</a>. The meeting will take place&nbsp;on July 25, 2025.
The United States Patent and Trademark Office (USPTO) issued patent number 12,274,692 <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45132313/exclusive-adial-pharmaceuticals-expands-patent-portfolio-with-new-us-patent-for-lead-drug-for-alcohol-and-opioid-use-disorders" rel="noreferrer noopener">to&nbsp;AD04 in May</a>.
The patent covers a method of treating alcohol-related diseases and opioid-related disorders using AD04 in genetically identified patients.
Price Action: ADIL stock closed at $0.59 on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45845302/unitedhealth-eyes-retreat-from-latin-america-after-8-3-billion-loss" target="_blank" rel="noreferrer noopener">UnitedHealth Eyes Retreat From Latin America After $8.3 Billion Loss</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

General

ADIL

EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial

Biotech

EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Engages with Cytel's Machine Learning Technology on Data Analysis and Phase 3 Trial Design'

EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Advances Toward Phase III Development For AD04

Telsey Advisory Group analyst Dana Telsey maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Market Perform and maintains $72 price target.

Price Target

Analyst Ratings

URBN

Telsey Advisory Group Maintains Market Perform on Urban Outfitters, Maintains $72 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Stitch Fix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) with a Market Perform and maintains $6 price target.

SFIX

Telsey Advisory Group Maintains Market Perform on Stitch Fix, Maintains $6 Price Target

Dollarama (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DOL#TSX">DOL</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.84 by 16.67 percent. This is a 27.27 percent increase over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $1.52 billion which beat the analyst consensus estimate of $1.50 billion by 1.40 percent. This is a 8.18 percent increase over sales of $1.41 billion the same period last year.

Earnings Beats

TSX:DOL

Dollarama Q1 EPS $0.98 Beats $0.84 Estimate, Sales $1.52B Beat $1.50B Estimate

HC Wainwright &amp; Co. analyst Ed Arce assumes Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Buy rating and announces Price Target of $30.

Initiation

TVTX

HC Wainwright & Co. Assumes Travere Therapeutics at Buy, Announces Price Target of $30

MNPR

Monopar And EDNOC Announce Expanded Access Program For MNPR-101-Zr And MNPR-101-Lu In Advanced Cancers

Telix Launches Gozellix PSMA-PET Imaging Agent In U.S. For Early, Precise Detection Of Prostate Cancer Metastases

Telsey Advisory Group analyst Dana Telsey maintains Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) with a Market Perform and lowers the price target from $5 to $4.

Telsey Advisory Group Maintains Market Perform on Designer Brands, Lowers Price Target to $4

Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) reported quarterly losses of $(0.19) per share. This is a 86.03 percent increase over losses of $(1.36) per share from the same period last year. The company reported $362.00 thousand in sales this quarter. This is a 7.74 percent increase over sales of $336.00 thousand the same period last year.

Rafael Holdings Q3 EPS $(0.19) Up From $(1.36) YoY, Sales $362.00K Up From $336.00K YoY

<ul>
<li>Offers an industry-leading portfolio of more than 30 solutions designed for air or liquid-cooled&nbsp;NVIDIA HGX&#x2122; B200, liquid-cooled NVIDIA GB200 NVL72, and NVIDIA RTX PRO 6000 Blackwell Server Edition</li>
<li>Speeds up time-to-online through&nbsp;NVIDIA Certified systems and NVIDIA Enterprise AI Factory Validated Designs</li>
<li>Future-ready solution stack supports upcoming&nbsp;NVIDIA GB300 NVL72 and HGX B300 NVL8 for seamless technology transitions</li>
</ul>

NVDA

SMCI

Supermicro Expands Blackwell-Powered AI Infrastructure Portfolio To Accelerate European Deployments

<a href="https://www.veeva.com/">Veeva Systems</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected <a href="https://www.veeva.com/medtech/products/clinical/">Veeva Clinical Platform</a> applications to simplify and streamline medical device and diagnostics studies. With increasing regulatory requirements and evolving markets, medtech companies are moving away from siloed legacy solutions to modern connected applications from <a href="https://www.veeva.com/medtech/">Veeva MedTech</a>.

VEEV

Veeva Systems Clinches Over 50 Medtech Clients As Industry Shifts From Outdated Tools To Smarter Clinical Platforms

Bread Financial May Net Loss Rate 8.0% Vs 8.8% Last Year; May Delinquency Rate 5.7% Vs 5.9% Last Year

Certified Method Enhances Global Botanical Quality and Safety

Herbalife's Aloe Vera Aloin Testing Method Earns AOAC INTERNATIONAL Certification

<a href="https://www.globenewswire.com/Tracker?data=OfwOMirWmDpdlw8EHrxWNYCbgyddw0lWaaXVxy5NoqI4I1FXn-ArnbOFGKcCOIz83UXtOraIk26dadMmQ9Lh2XpPbRWEooJrYrSkFIZ9V1k=">Pasithea Therapeutics Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, primary sclerosing cholangitis and ankylosing spondylitis.

KTTA

Pasithea Adds Drug Expert Dr. James Lee To Guide New Treatment For Crohn's And Other Inflammatory Diseases

Telsey Advisory Group analyst Cristina Fernandez maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Outperform and lowers the price target from $60 to $58.

Telsey Advisory Group Maintains Outperform on Academy Sports, Lowers Price Target to $58

Press Releases

Dolphin Subsidiary the Digital Dept. Hosts Highest-Grossing BRANDEdit Influencer Experience to Date in Los Angeles

Longtime Shore Fire Media Client Cyndi Lauper To Be Inducted Into Rock & Roll Hall of Fame

Dolphin Clients Shine at the 2025 Met Gala

Dolphin to Host First Quarter 2025 Earnings Call on May 13 at 4:30 PM ET

Dolphin Subsidiary The Digital Dept. Sees Surge In Affiliate Marketing Division, Driving Over $6.6 Million In Gross Retail Sales In First Quarter

Dolphin Reports Q1 2025 Results; Core Entertainment Publicity and Marketing Segment (EPM) Revenue Up 2% YoY to $12.1 Million, Strategic Investments and New Division Launch to Drive Long-Term Growth

Dolphin Subsidiary Special Projects Curates Star-Studded Guest List for the Tory Burch Store Opening on Rodeo Drive

Shore Fire Media Clients Shape the Summer 2025 Season With Star-Studded Music Festivals and Concert Series

Dolphin to Present at Maxim Group's 2025 Virtual Tech Conference

Dolphin Subsidiary Special Projects Partners with The Peabody Awards on 2025 Awards Ceremony

DLPN

Anghami

BloomZ

Brera Holdings PLC - Class B Ordinary Shares

Brera Holdings

Cineverse

Pop Culture Group Co., Ltd - Class A Ordinary Shares

Pop Culture Gr

Gaia

Global Mofy AI Limited - Class A Ordinary Shares

Global Mofy AI

Kuke Music Holding Limited American Depositary Shares (each representing ten (10) Class A Ordinary Shares)

Kuke Music Hldg

LiveOne

Moving iMage Technologies, Inc. Common Stock

Moving iMage Technologies

Mega Matrix

NIP Group Inc. - American Depositary Shares

NIP Group

PodcastOne

Reading International Inc - Class A Non-voting Common Stock

Reading Intl

Scienjoy Holding Corporation - Class A Ordinary Shares

Scienjoy Holding

Sound Group Inc. - American Depositary Shares

Comments

Dolphin Entertainment

Dolphin Entertainment (DLPN) Opzioni

Dolphin Entertainment (NASDAQ:DLPN) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO